Gateway 2011: 3M Drug Delivery Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gateway 2011: 3M Drug Delivery Systems



Your online Gateway to 3M Drug Delivery Systems in 2011

3M Center, Bldg. 275-3E-10
St. Paul, MN 55144
1-800-643-8086
www.3M.com/DDS


Don't miss 3M Drug Delivery Systems at Respiratory Drug Delivery, May 3-6, 2011 in Berlin, Germany

About 3M Drug Delivery Systems

For more than 50 years, pharmaceutical companies worldwide have looked to 3M Drug Delivery
Systems for ingenious inhalation (dry powder inhaler and metered-dose inhaler) and transdermal (microneedle
and drug-in-adhesive) solutions to help their products meet the needs of the market. With proven international
success in technology, development, manufacturing and regulatory, partnering with 3M helps ensure critical
speed to market and the technical success of your project.

Join Us at RDD

We’ll be showcasing 3M’s Drug Powder Inhalers as well as a variety of other inhalation drug delivery devices
and components.
We’re also offering a DPI: Design for Manufacturing and Scale-Up (DFMSU) workshop as well as several
poster presentations highlighting the most performance data from our new Dry Powder Inhalers. See “New Dry
Powder Inhaler Data at RDD Europe” below to learn more.
Visit us at the conference or set up a meeting to find out how our depth of resources can help enable your next
project’s success.

 

New Products
and Releases
New Whitepapers

RDD International Symposium

3M Conix™ Dry Powder Inhalers
New Dry Powder Inhaler Data at RDD Europe  

3M™ Taper Dry Powder Inhaler

 

 

 

 

 



ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here